Stay updated on AK104+Lenvatinib in Advanced Hepatocellular Carcinoma Clinical Trial
Sign up to get notified when there's something new on the AK104+Lenvatinib in Advanced Hepatocellular Carcinoma Clinical Trial page.

Latest updates to the AK104+Lenvatinib in Advanced Hepatocellular Carcinoma Clinical Trial page
- Check2 days agoChange DetectedThe web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an updated version number from v2.16.0 to v2.16.1.SummaryDifference2%
- Check9 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.3%
- Check16 days agoNo Change Detected
- Check31 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check46 days agoChange DetectedThe page has been updated to focus on a new study involving untreated metastatic pancreatic ductal adenocarcinoma, highlighting the drugs Cisplatin and Gemcitabine, while removing extensive details about a previous study involving multiple drugs and criteria.SummaryDifference30%
- Check53 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check96 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference2%
Stay in the know with updates to AK104+Lenvatinib in Advanced Hepatocellular Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the AK104+Lenvatinib in Advanced Hepatocellular Carcinoma Clinical Trial page.